Choose a Drug ! Aciphex Acomplia Actos Acyclovir Allegra Alli Diet Drug Altace Ambien Amoxicillin Atenolol Ativan Augmentin Avandia Avapro Baclofen Bactrim Biaxin Celebrex Celexa Cephalexin Champix Cialis Cipro Claritin D Clomid Coreg Depakote Diflucan Dilantin Diovan Doxycycline Effexor XR Elavil Estradiol Flomax Flonase Fluoxetine Folic Acid Fosamax Glucophage Hydroxyzine Ibuprofen Imitrex Keflex Lamisil Lasix Levaquin Levitra Lexapro Lipitor Mobic Naproxen Neurontin Nexium Norvasc Omeprazole Paxil Plavix Premarin Prevacid Promethazine Propecia Proscar Protonix Reductil Reglan Remeron Risperdal Singulair Sonata Synthroid Tamiflu Topamax Trazodone Ultra "C" tabs Ultra "L" tabs Ultra "V" tabs Ultram Viagra Wellbutrin Xenical Zithromax Zocor Zoloft Zyban Zyprexa Zyrtec

September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006

Opt-in for Free Newsletter, special discount offers, drugs information & latest pharmacy news.

Europe Backs Up Low-Dose Version of Cialis for Impotence

Having received approval from European officials, now Cialis turns the first erectile dysfunction drug which can be utilized constantly. According to the drug’s maker, Eli Lilly and Co., the European commission approved a once-daily version of pinnacle impotence pill Cialis.

So far, erectile dysfunction drugs like Cialis and Pfizer’s Viagra are permitted to be used when needed, but after the approval of European officials, a new low-dose formulation of Cialis, on the contrary, can be taken all the time, which in turn, exterminates the necessity to plan sexual activity in a restricted period of time. The pill is designed for men who want to reap sexual pleasure at least twice a week.

Lilly has planned to launch its once-daily version in certain European countries in the second half of this year.

In the first quarter of 2007, Cialis spawned worldwide sales of $266 and a once-daily version could assist the maker in differentiating its remedy from rivals, according to the estimate of industry analysts.